Back to search results

CCTA for Heart Disease Risk in Prostate Cancer Patients on ADT

This study is looking at how well a special type of scan, called Coronary CT Angiography (CCTA), can detect heart disease in men with prostate cancer who are receiving or about to start androgen deprivation therapy (ADT). ADT is a treatment that lowers male hormones. CCTA is a highly accurate way to find plaque in your heart arteries. The study wants to see what proportion of participants have atherosclerosis (hardening of the arteries) detected by CCTA and how many would be eligible for treatment based on these CCTA results. This study is currently unclear on its recruitment status and plans to enroll about 100 men.

Study design
This is a randomized pilot study, meaning participants are randomly assigned to either receive a CCTA scan or usual care. The study aims to include between 90 and 100 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes, including the proportion of atherosclerosis and eligibility for treatment, are measured at baseline (the start of the study).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05879913

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

Recruiting
NAAges 40+InterventionalDiagnostic
Indiana University
~100 participants
Updated 2026-02-25 on ClinicalTrials.gov
What's tested:Coronary CT Angiography (CCTA)

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of Atherosclerosis in CCTA Arm
Measured over Baseline
+1 more outcome measured

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

3 sites across 1 states
Indiana3

Study leadership

  • Abhishek Khemka, MD · PRINCIPAL_INVESTIGATOR · Indiana University

Who to contact

Elizabeth Rowe
[email protected]
(317) 278-1185
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Proportion of Atherosclerosis in CCTA ArmBaseline

    Proportion of prostate cancer patients without cardiac symptoms in the CCTA arm who are reclassified into a higher risk group using automated plaque assessment from CCTA that would otherwise be classed as low risk for ASCVD using the PCE

  • Proportion of Subjects Eligible for Treatment Based on Automated Plaque Assessment from CCTABaseline

    Assessment of automated plaque from CCTA determining eligibility of lipid lowering treatment and aspirin